TriSalus Life Sciences appoints David Patience as CFO; James Young resigns

TriSalus Life Sciences, Inc.

CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.
David Patience appointed CFO effective July 1, 2025; base salary $450,000, sign-on bonus $159,000, eligible for 50% annual bonus and 1% stock option grant.
Dan Giordano, VP of Finance, serves as acting CFO during transition; Young remains available for orderly handover.
Patience previously CFO at Accelerate Diagnostics; also held roles at Morgan Stanley, Continental Advisors, and Nuveen Investments.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Young

Chief Financial Officer

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-05-30
Successor: David Patience
Filed: May 30, 2025 23:59 UTC

Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.

Appointed

David Patience

Chief Financial Officer

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-07-01
Filed: May 30, 2025 23:59 UTC

On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.

Source: SEC EDGAR

accession 0001826667-25-000071

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.